✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Marksans Pharma Ltd.

MARKSANS

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹8,463 Cr.
P/E
24.17

Marksans Pharma Ltd.

  • Marksans Pharma
  • Strides Pharma Scien
  • FDC
  • TJI Pharma - Small Cap

FAQs on Marksans Pharma Ltd. Shareprice

Marksans Pharma has given better returns compared to its competitors.
Marksans Pharma has grown at ~18.16% over the last 8yrs while peers have grown at a median rate of 10.9%

Yes, Marksans Pharma is expensive.
Latest PE of Marksans Pharma is 24.65, while 3 year average PE is 19.61.
Also latest EV/EBITDA of Marksans Pharma is 15.89 while 3yr average is 12.91.

View FAQ's On Business

Growth Table

  • Marksans Pharma Ltd.
  • Strides Pharma Scien
  • FDC

Balance Sheet

  • Marksans Pharma Ltd.
  • Strides Pharma Scien
  • FDC

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Marksans Pharma Ltd.
  • Strides Pharma Scien
  • FDC

Cash Flow

  • Marksans Pharma Ltd.
  • Strides Pharma Scien
  • FDC

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Marksans Pharma Ltd.
  • Strides Pharma Scien
  • FDC

Quarterly Results

  • Marksans Pharma Ltd.
  • Strides Pharma Scien
  • FDC

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Marksans Pharma Ltd. Financials

Balance sheet of Marksans Pharma is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Marksans Pharma is decreasing.
Latest net debt of Marksans Pharma is -₹1,385.3 Crs as of Mar-25.
This is less than Mar-24 when it was -₹1,318.02 Crs.

The profit is oscillating.
The profit of Marksans Pharma is ₹352 Crs for TTM, ₹381 Crs for Mar 2025 and ₹314 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Marksans Pharma latest dividend payout ratio is 9.53% and 3yr average dividend payout ratio is 8.9%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech